Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

OTC Primatene Mist Returns: Market Future Bright After Cloudy NDA History

Nov 10 2018

• By Malcolm Spicer

FDABldg1ExteriorWithCircle_1200x675

Related Content

<em>Primatene Mist</em> CRL Underscores Challenges For OTC Asthma Treatments

Jan 04 2017

<em>Primatene Mist</em> Chances To Remain On Market Dwindle With Senate Vote

Nov 07 2011

Primatene Mist NDA Expected By July After FDA OKs OTC Asthma Inhaler Trial

Apr 20 2018

FDA Panel Votes Against Primatene Reboot Due To Safety Concerns

Feb 26 2014

Related Companies

Amphastar Pharmaceuticals, Inc.

Additional Topics

United States Approvals Drug Approval Standards Prescription To OTC Switch Launches Complete Response Letters Business Strategies Advisory Committees Advertising, Marketing & Sales OTC Drugs Respiratory Consumer

More from Rx-to-OTC Switch

More from Health

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window